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Transposition of the great arteries encompasses a set of structural congenital cardiac lesions that has in common ventriculoarterial discordance. Primarily because of advances
in medical and surgical care, an increasing number of children born with this anomaly are
surviving into adulthood. Depending upon the subtype of lesion or the particular corrective surgery that the patient might have undergone, this group of adult congenital heart
disease patients constitutes a relatively new population with unique medical sequelae.
Among the more common and difficult to manage are cardiac arrhythmias and other sequelae that can lead to sudden cardiac death. To date, the question of whether implantable cardioverter-defibrillators should be placed in this cohort as a preventive measure
to abort sudden death has largely gone unanswered. Therefore, we review the available
literature surrounding this issue. (Tex Heart Inst J 2015;42(4):309-18)

C

ardiac arrhythmias are a considerable problem among adult congenital heart
disease (ACHD) patients.1 Arrhythmias have been identified as the leading
cause of morbidity and hospitalization, and sudden cardiac death (SCD) is
known to be the most common cause of death in this group.1-4 Sudden cardiac death
in ACHD patients typically occurs in the 3rd to 4th decade of life, and patients with
ACHD are at up to a 100-fold increased risk of SCD when compared with agematched members of a control group.4,5
Within the spectrum of congenital heart disease (CHD), certain lesions have been
identified as conveying a particularly elevated risk of SCD.5 Among these is transposition of the great arteries (TGA),5 which accounts for 5% to 7% of all congenital cardiac malformations.6 The Centers for Disease Control and Prevention estimates that,
in the United States, approximately 1,900 babies are born annually with TGA, an
incidence of about 5 in every 10,000 live births.7 The increased risk for SCD in TGA
patients, specifically, is thought to result from a combination of sequelae consequent to
various surgical corrections, long-standing right ventricular (RV) strain, and abnormal
electrical architecture secondary to both genetic and physiologic stress.8-18 Together,
these abnormalities can lead to cardiac failure and arrhythmias as the affected child
grows into adulthood.8-18 In consequence, the indications for and value of implantable
cardioverter-defibrillators (ICD) in adult TGA patients is an area of considerable interest. Here we review the available data pertaining to ICD implantation for primary
prevention of SCD in adult TGA patients.
Background

Congenital TGA encompasses a group of structural cardiac lesions that has in common ventriculoarterial discordance—a state in which the aorta arises from the morphologic RV and the pulmonary artery (PA) arises from the morphologic left ventricle
(LV).14 As an entity, TGA is grossly subdivided into the dextro-type (D-TGA, or
complete TGA) and the levo-type (L-TGA, or congenitally corrected TGA) depending upon the type of ventricular looping that occurs during cardiogenesis.19 These
malformations frequently coexist with any number of congenital anomalies, includhttp://dx.doi.org/10.14503/THIJ-14-4352
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ing ventricular septal defect (VSD), atrial septal defect
(ASD), patent ductus arteriosus (PDA), and Ebstein’s
anomaly of the tricuspid valve.14,19
Complete TGA is the more prevalent of the 2 forms
of TGA.3,14 That defect is characterized by atrioventricular (AV) concordance: the left atrium (LA) empties into
the morphologic LV and the right atrium (RA) empties
into the morphologic RV, with ventriculoarterial discordance.14 This results in 2 parallel circulatory systems,
with pulmonary venous effluent returning again to the
lungs and systemic venous return being pumped once
again to the peripheral circulation.14,20 Maintenance of
oxygenation in the untreated state requires the presence
of a shunt lesion via an intracardiac defect (for example,
ASD, VSD, or PDA), which enables mixing of the systemic and pulmonary circulations.14,20 Even if a shunt
is present, however, the typical patient is profoundly
cyanotic at birth.20
Complete transposition generally requires a palliative
intervention at birth if a congenital shunt is not present
and, ultimately, corrective surgery in early infancy to
aid in patient survival.19-21 Such surgical interventions for
D-TGA are considered reparative, not curative.3 Until
the early 1980s, the best corrective surgery for D-TGA
patients was the atrial switch procedure, whereby systemic venous return was routed across the atrial septum
to the morphologic LV, and pulmonary venous return
was routed to the morphologic RV via intra-atrial baffles14,20 (Fig. 1). The first iteration of such surgeries (originally described in 1959), was the Senning procedure,
which used native atrial tissue to create the baffle.14,22
Subsequently, the Mustard procedure (first performed
in 1964) used Dacron or pericardial tissue to achieve the
same result.3,23 These atrial switch procedures created
AV discordance and left in place the ventriculoarterial
discordance characteristic of D-TGA.20 They also left
the morphologic RV responsible for maintenance of the
systemic circulation in these patients, frequently leading
to pump failure over time.20,24,25 Partly as a consequence
of these drawbacks of the atrial switch, the Mustard and
Senning procedures were largely abandoned by the late
1980s in favor of arterial switch operations (either the
Jatene or Rastelli, depending on the patient’s anatomy),
which in effect restored ventriculoarterial concordance
in D-TGA3,14,17 (Fig. 1). On early analysis, the arterial
switch procedure appears to decrease the predisposition
to pump failure and late arrhythmias that characterize
the atrial switch1,20,26-28; however, the cohort of D-TGA
patients who have undergone arterial switch procedures
is currently only in early adulthood.12,14
Conversely, L-TGA is characterized by AV discordance with concomitant ventriculoarterial discordance.3,14 As a result, the LA empties into the RV, which
then pumps blood to the aorta, and the RA empties
into the LV, which then pumps blood to the PA.14 This
configuration arises from a malrotation of the ventricles
310
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during cardiac organogenesis, leaving the morphologic
RV in the leftward and posterior position and the morphologic LV in the rightward and anterior position.19 In
the absence of other defects, affected patients will not be
cyanotic at birth.14,29 Consequently, their lesions might
be missed until they develop heart failure or undergo
cardiac imaging for an unrelated issue later in life.14,29
If not associated with other significant defects, L-TGA
does not require immediate surgical correction.29 Simultaneous atrial and arterial switch procedures in
these patients have been performed with the goal of
reestablishing AV and ventriculoarterial concordance,
in order to preserve the morphologic LV as the systemic
ventricle.30-33 However, because of the high perioperative
mortality rate and possible adverse sequelae of baffle
creation associated with this “double switch” procedure—in comparison with the relatively benign clinical
course of uncorrected L-TGA throughout the first 4 to
5 decades of life—this surgery is relatively rare.34
Risk of Arrhythmia and Sudden Cardiac Death

In improving long-term survival rates, the corrective
surgical procedures performed for TGA in the pediatric population have created a subset of ACHD patients
with unique long-term postoperative complications
and medical issues.35-37 From the cardiac standpoint,
the most recognized sequelae in this group are arrhythmias, RV dysfunction, and SCD.3,12,16,36-43 Among these,
arrhythmias are a leading cause of morbidity and hospitalization in TGA patients.12,13,36 A review by Deal44 published in 2011 revealed that TGA patients experience a
variety of arrhythmias, which include sinus node dysfunction, AV nodal block, supraventricular tachycardia
(SVT), and ventricular tachycardia (VT). Depending
upon the subtype of TGA (D- or L-) and the corrective surgery performed (atrial switch, arterial switch,
or double switch) the incidence of these arrhythmias
among TGA patients varies.44 In particular, Deal’s review showed that adult patients with D-TGA who
underwent arterial switch operations (for example, the
Jatene) had a lower incidence of arrhythmias overall
than did those who had undergone atrial switch procedures.44 This higher arrhythmic risk after the atrial
switch has been attributed to lines of conduction block
and isthmuses of slowed conduction (hence a substrate
for reentry) caused by the extensive atrial scarring associated with the Mustard and Senning operations.44
In a large meta-analysis directly comparing outcomes
of patients who had undergone Senning and Mustard
procedures, sinus node dysfunction was more often observed in those with Mustard corrections, but the data
regarding atrial tachyarrhythmias were not conclusively
different.45
Transposition patients are also known to be at increased risk of life-threatening arrhythmias.4,12,18,46-48
Sudden cardiac death is the leading cause of late death
Volume 42, Number 4, 2015
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Fig. 1 Schematic illustration of surgical interventions for the 2 subtypes of transposition of the great arteries. A) Reparative surgeries
for D-TGA include the atrial switch, the arterial switch, and the VSD baffle + conduit operation. The atrial switch (Mustard or Senning)
uses an intra-atrial baffle to redirect the systemic venous return to the morphologic left ventricle and the pulmonary venous return
to the morphologic right ventricle, effectively creating atrioventricular discordance. The arterial switch procedure (Jatene) involves
transsection of the aorta and the pulmonary artery, followed by re-anastomosis at the opposite roots, restoring ventriculoarterial concordance. The VSD baffle + conduit (Rastelli) operation creates a valved conduit from the right ventricle to the pulmonary artery and a
baffle from the left ventricle across a ventricular septal defect to the aortic valve. B) Surgical intervention for L-TGA includes the “double
switch” operation wherein simultaneous atrial redirection and arterial switch procedures are performed, again resulting in the presence
of an atrial baffle.
Ao = aorta; D-TGA = dextro-transposition of the great arteries; LA = left atrium; L-TGA = levo-transposition of the great arteries; LV = left
ventricle; PA = pulmonary artery; RA = right atrium; RV = right ventricle; VSD = ventricular septal defect

in patients with repaired cyanotic CHD (including
surgically corrected D-TGA).4,5 The overall incidence
of SCD in this particular group has been estimated to
be approximately 1 per 1,000 patient-years, and the risk
of SCD in ACHD patients is 25 to 100 times greater
than that in the general population.4,5 In 1998, Silka and
colleagues retrospectively investigated the frequency of
SCD among residents in the state of Oregon who had
undergone surgical treatment for CHD between 1958
and 1996.5 The authors found a marked diagnosis-dependent difference in the relative risk of late SCD among
patients with repaired CHD.5 The subgroup of D-TGA
patients, specifically, had an SCD incidence of 4.9 per
Texas Heart Institute Journal

1,000 patient-years, second only to the rate of congenital
aortic stenosis and 3-fold greater than that seen in tetralogy of Fallot (TOF) patients.5 Of note, all but one of
the D-TGA patients had previously undergone Mustard
procedures.5 Earlier series performed by Gelatt and associates12 and Gwelling and colleagues16 showed a similar
risk for SCD in D-TGA patients who had undergone
Mustard procedures. It is now recognized that among
ACHD patients, those with TGA who have had some
form of atrial switch operation are at the highest risk of
SCD, with an actuarial incidence approaching 10% by
20 years after surgery.5,12,17 In contrast, long-term and arrhythmia-free survival rates appear to be much better in
Primary Prevention of SCD in Adults with TGA
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D-TGA patients treated with the newer arterial switch
operation.27 Whether this benefit is attributable to hemodynamically unstable SVT or VT resulting from
atrial scarring after atrial redirection surgery or, rather,
to eventual systemic ventricular failure is currently unclear.49
Because of the high prevalence of SCD associated
with all subtypes of ACHD, there has been great interest in identifying clinical risk factors that predispose patients in this group to cardiac events.50 Signal-averaged
electrocardiograms (SAECG) and T-wave alternans
(TWA) exercise studies have been investigated on a
very limited basis as means of identifying those at risk
for the development of life-threatening arrhythmias
within the CHD population.51,52 Results of one prospective study did suggest that positive SAECG results
connote the presence of a slow conduction substrate
and the risk of monomorphic VT in those patients
who had previously undergone right ventriculotomy
for repair of CHD.51 Ultimately, SAECG and TWA
do not accurately predict SCD risk in this group, and
neither investigative technique is routinely used in clinical practice. As with other forms of CHD, investigators
have attempted to define clinical predictors of SCD,
specifically in D-TGA patients who have undergone
atrial switch procedures.15,18,49,53 Most have suggested
that both atrial tachyarrhythmias and RV failure (including RV dysfunction measured by echocardiography
and heart failure indicated by symptoms) are risk factors for late SCD.12,18,49,53 Other studies have shown that
the late development of spontaneous VT or ventricular
fibrillation (VF) might be more prevalent in this patient
population than has been reported.5,14,15 Risk factors for
VT and SCD in these observational studies included a
QRS duration ≥140 ms, an older age at surgical repair,
and systemic ventricular dysfunction.15 More recently, a
retrospective study of 89 TGA patients found that older
age at intervention (either Mustard or Senning), surgery
during an earlier year (median, 1971 vs 1975), and a
history of atrial arrhythmias conveyed an increased risk
of SCD within this group.54 Unfortunately, conclusive
identification of the cause of SCD (for example, severe
pump failure, poorly tolerated SVT, or ventricular arrhythmia) and, therefore, formulation of a reliable and
validated risk metric for its prediction remain elusive in
this particular population.30,44
Implantable Cardioverter-Defibrillator
Placement in TGA Patients

Antiarrhythmic agents, ablative techniques, and implantation of a permanent pacemaker or internal defibrillator
have been used to treat a wide spectrum of arrhythmic
conditions in ACHD patients.1,3,55-57 Although multiple
pharmacotherapeutic and interventional options are
regularly applied, few high-quality data exist on the
specific indications for and efficacy of these treatments
312
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`in any diagnostic group among this cohort.3,56 Rather,
general guiding principles for the management of cardiac patients without CHD (but with similar medical
problems) tend to dictate decision-making.3,56
Multiple strategies for the prevention and management of malignant arrhythmias have been implemented
over the years. Currently, the ICD has assumed a principal role,50 but the indications for ICD placement in
CHD patients remain controversial: expert opinion
varies, and there are few additional data upon which
to base recommendations.50 For secondary prevention,
decisions to place an ICD in both pediatric and adult
CHD patients are fairly straightforward.50 It is generally agreed that such patients can benefit from device
implantation if they have survived cardiac arrest or a
sustained episode of VT with hemodynamic compromise—provided that neither a definitive reversible
cause nor a terminal illness with a life expectancy of less
than one year exists.50,56 On the other hand, the decision
to place an ICD for the purposes of primary prevention
in an asymptomatic or minimally symptomatic patient
is less clear. Increasing numbers of case reports, studies,
and reviews have recently focused on outcomes of ICD
placement in pediatric and adult CHD patients.1,3,9,50,55-65
Some authors58,62 have attempted to create risk-stratification schemata for determining which patients might
benefit from ICD placement for primary prevention,
either through retrospective analysis of SCD incidence
in a group of patients without a device, or through retrospective analysis of clinical predictors of appropriate
shock delivery among patients with ICDs in place.
Unfortunately, increased frequency of device complications, suboptimal risk-stratification schemes to guide
patient selection, uncertainty regarding efficacy, and
challenging patient anatomy make the introduction of
an ICD for primary prevention in CHD patients an
extremely complex decision.50 Although it is not unusual for ICDs to be implanted for primary prevention
in symptomatic patients with failing systemic ventricles, the validity of extrapolating data from the primary
prevention trials of patients without CHD, and then
applying them to the ACHD cohort, is questionable.57
Moreover, standard indications to implant an ICD for
primary prevention are present only in a minority of
ACHD patients who undergo such procedures.55,56
Sudden cardiac death is known to be the most frequent cause of death among TGA patients who have
previously undergone an atrial switch, with an observed
incidence between 2% and 15%.5,13,21,43,53,66-69 However,
identifying a high-risk subgroup within this population has also proved to be difficult.49 Bradyarrhythmias
were once thought to be the primary trigger of SCD in
this group. That theory was questioned and ultimately
was refuted, when retrospective evidence showed that
pacemakers did not confer protection from sudden
death.38,39
Volume 42, Number 4, 2015

The largest analysis of ICD implantation in D-TGA
patients (specifically) was published in 2008 by Khairy
and colleagues.49 This multicenter study attempted
to identify clinical predictors of appropriate shock,
determine the rates of appropriate and inappropriate
shock delivery, and characterize complications in this
group.49 Retrospective data were collected on a total of
37 D-TGA patients (mean age, 28 ± 7.6 yr) who had
previously undergone an atrial switch procedure. Approximately 62% of these patients had ICDs placed for
primary prevention, whereas the rest had devices implanted for secondary prevention. Justifications for primary prevention implantation in this cohort included
presyncope, syncope, palpitations, nonsustained VT
(NSVT), systemic RV ejection fraction (EF) ≤0.35,
QRS duration ≥180 ms, and inducible sustained VT
on electrophysiologic study.49 Those with ICDs placed
for primary prevention tended to be older at the time
of implantation, had a higher prevalence of NSVT, and
were more likely to exhibit moderate or severe RV systolic dysfunction than were their counterparts whose
devices had been placed for secondary prevention. Ultimately, the investigators concluded that a high rate of
appropriate shocks occurred among patients with ICDs
placed for secondary prevention, but that the rate of
such shocks was exceedingly low in patients with devices placed for primary prevention. Other germane
findings of this study were that patients not prescribed
β-blockers experienced higher rates of appropriate
shocks, that inducible VT on electrophysiologic study
was not predictive of appropriate shocks, and that supraventricular arrhythmias can themselves lead to ventricular tachyarrhythmias.49 Aside from this isolated study
by Khairy and colleagues,49 data regarding outcomes of
ICD implantation in this patient population are largely
limited to case reports70 and small series,61,71 or to studies of CHD patients as a pooled group.58-62,64,65,72 Unfortunately, subgroup analysis by underlying congenital
anomaly was not routinely performed in the latter.
Therefore, specific outcomes in D- and L-TGA patients
are difficult to evaluate. One case series 71 did identify
5 D-TGA patients who, after Mustard surgery, underwent ICD placement for primary prevention at a single
institution and found that no shocks were delivered to
the subjects during a follow-up period of 24 months.
Because no shocks were delivered, no judgments could
be made in regard to the risk for appropriate shock.71
Data on the benefit of ICD therapy in adult congenital patients with, specifically, surgically treated or untreated L-TGA are even more limited. Although current
dogma holds that systemic ventricular dysfunction and
history of atrial arrhythmias in TGA patients who have
undergone some form of intra-atrial redirection surgery
are indicative of increased risk of SCD, the data remain
less than definitive for the placement of ICDs for primary prevention.
Texas Heart Institute Journal

Device implantation in TGA patients who have undergone atrial redirection surgery is not without challenge and risk, and the hazard of inappropriate ICD
placement should not be underestimated. The potential
for inappropriate shocks delivered from a device placed
either for primary or secondary prevention and the resultant anguish posed to individuals within this group
are very real.50,73-77 Implantable cardioverter-defibrillators
are known to confer survival benefit among patients
at risk for SCD with primary prevention indications
(low LV ejection fraction with a structurally normal
heart).78-82 However, inappropriate shocks—whether
for atrial arrhythmias with rapid ventricular conduction or for abnormal sensing—result in multiple adverse
effects that can include impaired quality of life, psychiatric disturbances, and even provocation of nonfatal or
fatal ventricular arrhythmias.83 Because TGA patients
are predisposed to such rhythm disturbances, the implantation of ICDs for primary prevention in this group
is not entirely benign. In fact, in a recently published
trial of 59 ACHD patients who had ICDs placed for
both primary and secondary prevention, adults with
non-TOF congenital heart lesions (D-TGA, L-TGA,
double-outlet RV, Shone complex, isolated pulmonary
atresia, total anomalous pulmonary venous return,
AV canal defect, and secundum ASD) received fewer
appropriate ICD therapies but had an equivalent rate
of inappropriate ICD therapies, when compared with
their TOF counterparts over a median follow-up period
of 3.2 years.72 Although subanalysis of ICD therapies
was not performed among the non-TOF patients, these
findings do suggest that the benefit of ICD implantation can vary by underlying ACHD lesion (TOF vs
non-TOF) and that the increased relative risk of ICD
shocks and complications might outweigh the usefulness of devices placed for traditional indications in the
non-TOF population.72
In addition to the difficulty of identifying clinical
risk factors for SCD within the TGA patient population and the propensity for inappropriate shock delivery
once ICDs are placed, one must consider complications
surrounding the implantation and maintenance of devices when conducting a risk–benefit analysis of ICD
placement for primary prevention.49,50 Because of the
altered anatomy, created not only by the defect itself
but by the baffle repair, technical challenges to the implantation of leads can be considerable.3,57 Baffle obstruction has been reported in 36% of TGA patients,
with systemic venous pathway obstruction occurring
3.5 times more frequently in Mustard than in Senning
repairs.45 Consequently, vascular access limitations
might preclude transvenous lead placement that requires epicardial systems.1,53,55,57 If a transvenous device
is successfully placed, the chronic presence of a bulky
lead in the superior limb of the atrial baffle can predispose patients to baffle stenosis 84-86 (Fig. 2). In addiPrimary Prevention of SCD in Adults with TGA
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Fig. 2 Lateral fluoroscopic view of a patient with baffle stenosis,
a consequence of pacemaker lead placement through an atrial
baffle. The pacemaker generator is seen giving rise to the atrial
and ventricular leads, both of which travel through the original
atrial baffle. The stenotic portion of the baffle (arrow) has caused
dilation of the superior vena cava and of the azygos venous
system.
A = atrial pacemaker lead; AV = azygos vein; PM = pacemaker
generator; SVC = superior vena cava; V = ventricular pacemaker
lead

tion, because of the relative position of the ventricles in
D-TGA after an atrial switch, the systemic ventricle is
not interposed between the device coil and generator
as it normally would be in traditional transvenous ICD
lead placement.71 This is thought to have a significant
effect on defibrillation thresholds and efficacy.71,87 Finally, in ACHD patients who have had ICDs placed
for either primary or secondary prevention, lead failure
is the most frequently reported device-related complication.50,55 This is probably due to a combination of
unusual anatomy and the younger average age of the
cohort in whom these devices are implanted, predisposing leads to either passive or traumatic fracture.50
Very few current data exist on the usefulness and
benefit of epicardial devices or subcutaneous arrays for
cardiac defibrillation within the ACHD patient population. Evidence suggests that subcutaneous arrays are less
effective than transvenous devices with regard to defibrillation thresholds.71 This drawback might be mitigated by selecting patients with smaller body sizes and
incorporating intrathoracic electrodes in those chosen
for subcutaneous systems.71 Although epicardial devices
do not appear to be inferior to transvenous defibrillators
for the primary prevention of SCD (according to the
limited data available for this group), the placement of
314
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epicardial patches requires an open-chest procedure.71
Because the implantation of such systems introduces an
increased procedural risk and can lead to adverse consequences, including constriction and bleeding, epicardial
patches have largely been abandoned.55
In 2008, 2 review articles published in Circulation:
Arrhythmia and Electrophysiology considered the matter of whether patients with CHD who had a systemic
ventricular EF of <0.30 should undergo prophylactic
ICD implantation.73,88 From the opposing viewpoint,
Triedman73 posited that CHD patients are significantly
different from populations in other primary prevention
studies63 and that current evidence suggesting a lack of
appropriate shocks60,61,64,89 and an adverse effect on quality of life 75-77 argue against routine ICD placement for
primary prevention in ACHD patients with EF <0.30.
He suggested, rather, that ventricular function should
be a crucial input in a multifactorial, patient-specific
approach to risk evaluation in this population.73
From the supportive viewpoint, Silka and Bar-Cohen88 asserted that there is a definite association between advanced systemic ventricular dysfunction and
SCD in specific forms of postoperative CHD (chief
among them, D-TGA after atrial switch repair). In consideration of the advances in ICD technology and the
benefits that MADIT II and SCD-HeFT revealed in
non-CHD patients with an EF <0.30,78,81 the authors
contended that ICD placement for primary prevention
in ACHD patients with failing systemic ventricles has
a high probability of benefit.88
Although the above reviews concerned ICD implantation in CHD patients in general, rather than in
TGA patients in particular, many of the conclusions
were drawn from evidence that included TGA subjects.
Hence the question of whether TGA patients should
routinely receive ICDs for primary prophylaxis remains
highly complicated (Table I). The lack of high-quality
clinical evidence for the examination of outcomes in a
large number of TGA patients with ICD placement is
the most substantial impediment to resolving this issue.
Studies similar to that performed by Khairy and colleagues49 would probably provide essential data both on
the causes that underlie SCD (that is, pump failure,
SVT, or VT/VF) and on the efficacy of ICD therapy
in preventing those events. Only from this kind of information will recommendations arise that are likely to
benefit this patient population. On the basis of current
evidence, the primary disadvantages to ICD placement
in this group appear to be a high frequency of inappropriate shocks, difficulty in device implantation, complications that include (but are not limited to) lead fracture
and failure, and uncertain efficacy in preventing SCD.
As ICD technology improves and procedural strides
are made in the application of such devices, some of
these issues might become less problematic. Nevertheless, without resolution of the fundamental uncertainty
Volume 42, Number 4, 2015

TABLE I. Key Determinants of ICD Implantation in Adult TGA Patients for Primary Prevention of SCD
Factors Favoring ICD Implantation

Factors Opposing ICD Implantation

High degree of association between systemic ventricular
dysfunction and SCD

Unestablished cause of SCD: tachyarrhythmias (i.e.,
supraventricular or ventricular), ventricular failure, or both

Established survival benefit in non-ACHD patients with
ventricular failure

Lack of evidence-based survival benefit for primaryprevention ICD placement

Limited evidence supporting survival benefit in ACHD
patients who have secondary implantation indications

High frequency of inappropriate shocks

Advancing ICD technology

Device-related complications (primarily lead fracture and
failure)
Poor defibrillation thresholds for implanted devices, due to
altered anatomy

ACHD = adult congenital heart disease; ICD = implantable cardioverter-defibrillator; SCD = sudden cardiac death; TGA = transposition
of the great arteries

regarding the efficacy of ICDs in this cohort, ICD
implantation will not and should not be viewed as the
standard of care; rather, it should be applied on a caseby-case basis. When considering an ICD for primary
prevention, a number of factors, including the presence
of atrial or ventricular arrhythmias, systemic ventricular dysfunction, and the severity of symptoms should
be included in the evaluation of a TGA patient before
proceeding with device placement. Family support, lifestyle, and psychological burden should be factored into
the decision-making process as well.
The implantation of ICDs in TGA patients as secondary prevention, however, appears to be supported
by the sparse data that are available. Khairy and colleagues49 indicated that patients with ICD implants for
secondary prevention were significantly more likely to
experience arrhythmia, and subsequently to receive appropriate therapy. This, in combination with data indicating that antiarrhythmic drugs do not confer the same
protection,81 argues in favor of ICD implantation in this
subpopulation. These patients probably should be prescribed concurrent β-blockers, because there is some indication that β-blockade suppresses primary ventricular
arrhythmias and affords protection against appropriate
shocks in those who already have devices in place.49
Conclusion

As with many other questions in ACHD, that of ICD
implantation for primary prevention in TGA patients
remains unresolved. Furthermore, as the number of
patients who have previously undergone atrial switch
procedures has probably peaked and eventually will be
surpassed by those with arterial switch repairs, the risk
of SCD in TGA patients is going to change. All factors indicate that the probability of this complicated
question’s being answered in a broadly applicable way
is remote. For the foreseeable future, ICD implantation
in TGA patients will continue to be recommended on
Texas Heart Institute Journal

a case-by-case basis, with careful consideration of the
multiple facets of the decision.
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